What is the current Next-Generation Antibody Therapeutics Market size?

The Next-Generation Antibody Therapeutics Market is projected to register a CAGR of 12.10% during the forecast period (2024-2029) Read More

Who are the key players in Next-Generation Antibody Therapeutics Market?

AstraZeneca Plc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Pfizer, Inc. and Seagen Inc. are the major companies operating in the Next-Generation Antibody Therapeutics Market. Read More

Which is the fastest growing region in Next-Generation Antibody Therapeutics Market?

Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029). Read More

Which region has the biggest share in Next-Generation Antibody Therapeutics Market?

In 2024, the North America accounts for the largest market share in Next-Generation Antibody Therapeutics Market. Read More

What years does this Next-Generation Antibody Therapeutics Market cover?

The report covers the Next-Generation Antibody Therapeutics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Next-Generation Antibody Therapeutics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Next-Generation Antibody Therapeutics Market Share

Statistics for the 2023 & 2024 Next-Generation Antibody Therapeutics market share, created by Mordor Intelligence™ Industry Reports. Next-Generation Antibody Therapeutics share report includes a market forecast to 2029 and historical overview. Get a sample of this industry share analysis as a free report PDF download.

Market Share of Next-Generation Antibody Therapeutics Industry

The market for next-generation antibody therapeutics is moderately competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some prominent players are acquiring other companies to consolidate their market positions across the globe, while others are launching new products. Some of the companies that are currently dominating the market are Amgen Inc., AstraZeneca Plc., Bayer AG, Biogen, Bristol-Myers Squibb Company, GlaxoSmithKline Plc., F. Hoffmann-La Roche Ltd., ImmunoGen Inc., Kyowa Hakko Kirin Co., Ltd., Pfizer Inc., Seagen Inc., and Xencor, Inc., among others.